Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Elena Argento, Steffanie A. Strathdee, Kenneth W. Tupper, Melissa Braschel, Evan Wood, Kate Shannon
BMJ Open September 1, 2017 DOI: 10.1136/bmjopen-2017-016025 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Longitudinal community-based cohort study Peer reviewed |
|---|---|
| Sample size | 290 |
| Population | Marginalised women in Metro Vancouver, Canada, without suicidality at baseline |
| Duration | 54-month follow-up |
| Keywords | Suicidal ideation Hazard ratio Cohort study Longitudinal study Poison control Proportional hazards model Substance abuse Mental health Suicide prevention Incidence geometry Confidence interval Medical emergency |
| Citations | 60 |
| Key findings | Lifetime psychedelic drug use was associated with a 60% reduced hazard for new suicidality (adjusted HR 0.40; 95% CI 0.17 to 0.94). |
Abstract
Objective: This study aimed to longitudinally investigate whether ever having used a psychedelic drug can have a protective effect on incidence of suicidality among marginalised women.
Design: Longitudinal community-based cohort study.
Setting: Data were drawn from a prospective, community-based cohort of marginalised women in Metro Vancouver, Canada.
Participants: 766 women completed the baseline questionnaire between January 2010 and August 2014. Participants who did not report suicidality at baseline and who completed at least one follow-up visit were included. Main outcome measure Extended Cox regression was used to model predictors of new suicidality (suicide ideation or attempts) over 54-month follow-up.
Results: Nearly half (46%; n=355) of participants reported prior suicidality and were thus excluded from the present analyses. Of 290 women eligible at baseline, 11% (n=31) reported recent suicidality during follow-up, with an incidence density of 4.42 per 100 person-years (95% CI 3.10 to 6.30). In multivariable analysis, reported lifetime psychedelic drug use was associated with a 60% reduced hazard for suicidality (adjusted HR (AHR) 0.40; 95% CI 0.17 to 0.94). Crystal methamphetamine use (AHR 3.25; 95% CI 1.47 to 7.21) and childhood abuse (AHR 3.54; 95% CI 1.49 to 8.40) remained independent predictors of suicidality.
Conclusion: The high rate of suicidality identified in this study is of major concern. Alongside emerging evidence on the potential of psychedelic-assisted therapy to treat some mental illness and addiction issues, our findings demonstrate that naturalistic psychedelic drug use is independently associated with reduced suicidality, while other illicit drug use and childhood trauma predispose women to suicidality. While observational, this study supports calls for further investigation of the therapeutic utility of psychedelic drugs in treating poor mental health and promoting mental wellness.
Citations in the library
Cited by 53
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- Predicting Responses to Psychedelics: A Prospective Study Frontiers in Pharmacology November 2, 2018
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Unifying Theories of Psychedelic Drug Effects Frontiers in Pharmacology March 2, 2018
and 48 more in the library
Cites 30
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
and 25 more in the library